Valencia pharmaceuticals concern MannKind has a $925 million global agreement with Paris’ Sanofi to sell and market Afrezza, the inhalable insulin drug that received FDA approval less than two months ago, Bloomberg said.

For reprint and licensing requests for this article, CLICK HERE.